Share of Clicks for top 10 US Pharma & Biotech Research and Development brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| lilly.com | 26.3 |
| merck.com | 6.64 |
| regeneron.com | 5.07 |
| ro.co | 4.88 |
| gsk.com | 4.53 |
| pfizerforall.com | 4.14 |
| evenity.com | 4.1 |
| modernatx.com | 3.62 |
| sequencing.com | 2.08 |
| abbvie.com | 1.99 |
| others | 36.65 |
- lilly.com - 26.3%
- merck.com - 6.64%
- regeneron.com - 5.07%
- ro.co - 4.88%
- gsk.com - 4.53%
- pfizerforall.com - 4.14%
- evenity.com - 4.1%
- modernatx.com - 3.62%
- sequencing.com - 2.08%
- abbvie.com - 1.99%
- others - 36.65%
Copyright © Adthena. All rights reserved.
Lilly.com leads with 26.3% click share, while ‘others’ collectively hold 36.65%, showcasing diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Research and Development brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | lilly.com | evenity.com | novonordisk-us.com | pfizerforall.com | ro.co | wegovy.com | merck.com | scemblix.com | ubrelvyhcp.com | hims.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/10/01 | 23.92% | 9.24% | 0% | 5.87% | 4.53% | 4.49% | 2.11% | 1.01% | 3.03% | 0.9% |
| 2026/10/02 | 24.21% | 9.7% | 0% | 6.2% | 4.06% | 3.99% | 2.88% | 1.57% | 3.22% | 1.11% |
| 2026/10/03 | 27.21% | 9.17% | 0% | 5.47% | 2.8% | 3.75% | 3.13% | 1.58% | 3.42% | 0.73% |
| 2026/10/04 | 28.21% | 8.4% | 0% | 4.7% | 4.1% | 3.16% | 3.04% | 1.64% | 3.3% | 1.13% |
| 2026/10/05 | 21.42% | 9.98% | 0% | 6.53% | 3.08% | 4.39% | 2.68% | 1.59% | 4.56% | 0.66% |
| 2026/10/06 | 22.02% | 9.9% | 0% | 6.51% | 5.31% | 2.21% | 2.67% | 2.03% | 2.57% | 0.02% |
| 2026/10/07 | 20.09% | 9.26% | 0% | 6.62% | 9.13% | 1.83% | 2.99% | 1.86% | 1.9% | 1.29% |
| 2026/10/08 | 23.46% | 7.67% | 0% | 5.45% | 8.66% | 1.87% | 2.59% | 1.17% | 2.33% | 1.78% |
| 2026/10/09 | 21.72% | 8.5% | 0% | 6.68% | 5.43% | 1.41% | 2.5% | 1.29% | 3.3% | 1.58% |
| 2026/10/10 | 26.74% | 7.62% | 0% | 5.34% | 5.99% | 2.85% | 2.77% | 1.58% | 1.77% | 2.05% |
| 2026/10/11 | 24.83% | 7.39% | 0% | 5.16% | 8.88% | 1.64% | 2.57% | 1.41% | 2.05% | 0.87% |
| 2026/10/12 | 21.94% | 9.08% | 0% | 6.29% | 2.97% | 1.79% | 3.24% | 2.09% | 1.57% | 0.04% |
| 2026/10/13 | 18.04% | 8.54% | 0% | 5.14% | 6.08% | 2.08% | 2.46% | 1.68% | 2.03% | 1.09% |
| 2026/10/14 | 18.86% | 8.75% | 0% | 5.57% | 8.25% | 2.03% | 2.49% | 1.6% | 1.4% | 0.46% |
| 2026/10/15 | 19.74% | 7.9% | 1.29% | 5.07% | 8.2% | 0.63% | 2.4% | 1.78% | 1.35% | 2.1% |
| 2026/10/16 | 19.57% | 7.2% | 4.2% | 5.37% | 9.14% | 0.92% | 2.16% | 1.5% | 2% | 3.04% |
| 2026/10/17 | 22.11% | 6.37% | 5.84% | 4.28% | 10.54% | 1.72% | 2.92% | 1.24% | 1.53% | 2.46% |
| 2026/10/18 | 22.97% | 7.08% | 4.86% | 5.12% | 6.76% | 1.08% | 3.78% | 1.3% | 1.81% | 2.7% |
| 2026/10/19 | 20.72% | 6.87% | 4.16% | 5.92% | 10.23% | 0.61% | 2.19% | 1.54% | 1.83% | 2.77% |
| 2026/10/20 | 16.64% | 7.69% | 4.86% | 6.35% | 11.28% | 0.52% | 1.93% | 1.05% | 1.48% | 3.07% |
| 2026/10/21 | 16.35% | 7.23% | 4.74% | 5.49% | 11.8% | 1.02% | 2.08% | 1.39% | 1.03% | 3.18% |
| 2026/10/22 | 15.02% | 8.16% | 4.33% | 5.92% | 9.48% | 2.83% | 2.12% | 1.68% | 0.86% | 1.97% |
| 2026/10/23 | 19.46% | 8.37% | 0% | 6.03% | 9.45% | 1.45% | 2.6% | 1.53% | 0.68% | 1% |
| 2026/10/24 | 23.3% | 7.51% | 0% | 5.25% | 8.26% | 1.87% | 2.14% | 1.19% | 1.65% | 1.84% |
| 2026/10/25 | 21.97% | 7.73% | 0.01% | 4.96% | 7.37% | 2.77% | 2.34% | 1.34% | 1.48% | 0.39% |
| 2026/10/26 | 19.07% | 8.6% | 2.71% | 5.35% | 9.33% | 2.4% | 1.78% | 1.48% | 1.15% | 0.43% |
| 2026/10/27 | 13.32% | 8.19% | 5.13% | 5.54% | 10.77% | 2.53% | 1.35% | 1.28% | 1.32% | 1.46% |
| 2026/10/28 | 16.9% | 8.46% | 5.67% | 6.37% | 8.47% | 3.65% | 1.43% | 1.54% | 0.84% | 1.02% |
| 2026/10/29 | 14.08% | 8.58% | 2.79% | 6.05% | 11.48% | 3.22% | 1.37% | 1.52% | 0.19% | 1.17% |
| 2026/10/30 | 21.58% | 8.23% | 4.77% | 5.59% | 6.92% | 3.36% | 1.58% | 1.3% | 0.83% | 1.46% |
| 2026/10/31 | 23.52% | 9.03% | 5.89% | 5.22% | 3.24% | 2.25% | 1.94% | 1.72% | 0.77% | 0.64% |
- lilly.com
- evenity.com
- novonordisk-us.com
- pfizerforall.com
- ro.co
- wegovy.com
- merck.com
- scemblix.com
- ubrelvyhcp.com
- hims.com
Copyright © Adthena. All rights reserved.
In October 2026, lilly.com led with fluctuating spend, peaking early and stabilizing. Evenity.com maintained a steady presence, while ro.co surged mid-month. Novo Nordisk and Pfizer showed consistent activity. The month concluded with diverse strategies across domains.
Competitor Count for US Pharma & Biotech Research and Development
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/10/01 | 375 |
| 2026/10/02 | 375 |
| 2026/10/03 | 353 |
| 2026/10/04 | 357 |
| 2026/10/05 | 364 |
| 2026/10/06 | 372 |
| 2026/10/07 | 372 |
| 2026/10/08 | 374 |
| 2026/10/09 | 371 |
| 2026/10/10 | 368 |
| 2026/10/11 | 358 |
| 2026/10/12 | 384 |
| 2026/10/13 | 402 |
| 2026/10/14 | 401 |
| 2026/10/15 | 390 |
| 2026/10/16 | 383 |
| 2026/10/17 | 398 |
| 2026/10/18 | 391 |
| 2026/10/19 | 401 |
| 2026/10/20 | 391 |
| 2026/10/21 | 396 |
| 2026/10/22 | 399 |
| 2026/10/23 | 400 |
| 2026/10/24 | 408 |
| 2026/10/25 | 416 |
| 2026/10/26 | 421 |
| 2026/10/27 | 419 |
| 2026/10/28 | 422 |
| 2026/10/29 | 424 |
| 2026/10/30 | 415 |
| 2026/10/31 | 416 |
Copyright © Adthena. All rights reserved.
October began with 375 advertisers, dipped mid-month, then surged to 424 by the 29th, closing at 416.
